Skip to content

Observational Dutch Young Symptomatic StrokE studY - nEXT

Observational Dutch Young Symptomatic StrokE studY - Extended

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05853796
Acronym
ODYSSEY-nEXT
Enrollment
280
Registered
2023-05-11
Start date
2023-02-06
Completion date
2037-01-01
Last updated
2023-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Cerebrovascular Disorders, Coagulation, Embolism and Thrombosis, Ischemic Stroke, Stroke in the Young, Thrombophilia

Brief summary

BACKGROUND: Worldwide, 2 million patients aged 18-50 years suffer an ischemic stroke each year with an increasing trend over the past decade due to yet unknown reasons. Whereas prognosis and antithrombotic treatment in older patients with cardiovascular disease are among the best studied topics in clinical medicine, this does not hold true for patients at young age. It is of great importance to treat these patient groups correctly to prevent recurrence and bleeding complications. However, previous research have shown that there is a long-term increased risk of recurrent ischemic events despite the secondary prevention and a subsequent increased bleeding risk. To tailor effective antithrombotic therapy to the individual patient, it is essential to understand the underlying pathogenesis and identify modifiable risk factors in young patients for recurrence or bleeding. It is thought that abnormalities of hemostasis may play a key role in early-onset ischemic stroke. First, prothrombotic conditions are associated with an increased risk for ischemic stroke at young age. In addition, disturbance of the hemostatic balance due to one or several triggers can activate the coagulation cascade, which on its turn can lead or contribute to clot formation and subsequent arterial occlusion. In previous study, there were indications that trigger factors such as fever and/or an infection in the days prior to the stroke may play a role in the pathogenesis. This suggests that an interaction between inflammation, endothelial damage and coagulation may lead to the formation of a clot. In this observational study we aim to investigate the role of the immune system, endothelial damage and coagulation in the pathogenesis and prognosis of stroke in young patients. OBJECTIVE: To investigate the role of hemostasis, inflammation and endothelial activation in the etiology and prognosis in an acute ischemic stroke (or TIA) in young stroke patients. STUDY DESIGN: Multicentre prospective observational study STUDY POPULATION: All patients aged between 18 and 50 years old with a first-ever ischemic stroke or TIA who are admitted to the neurology ward or seen at the outpatient clinic of one of the participating centers. Main exclusion criteria are: history of clinical TIA, ischemic stroke or intracerebral hemorrhage. A intracerebral hemorrhage resulting from trauma, known aneurysm or underlying intracerebral malignancy. A venous infarction, retinal infarction and amourosis fugax. Inadequate control of the Dutch language to reliably sign an informed consent from and/or participate in the follow-up. Patients are excluded if they have a contra indication for 3T MRI. In addition 60 healthy controls (18-50 years old) will be included. MAIN STUDY ENDPOINTS: 1. Baseline and 3 months coagulation profile: Whole blood and platelet poor plasma thrombin generation, platelet function tests, and coagulation biomarkers, screening for thrombophilia. 2. Baseline and 3 months inflammation/endothelial activation profile: Cytokines/chemokines, expression of receptors/cofactors related to hemostasis on peripheral blood mononuclear cells (PBMCs), stimulation tests of PBMC's to assess trained immunity. 3. Vessel wall enhancement on 3 Tesla MRI 4. Questionnaire trigger factors

Interventions

None listed

Sponsors

Synapse bv
CollaboratorINDUSTRY
Radboud University Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years

Inclusion criteria

* Patients with a first-ever transient ischemic attack (TIA) or acute ischemic stroke aged between 18 and 50 years old * For this study, acute stroke is defined as occurence of acute neurological deficit lasting more than 24 hours, with confirmation on imaging (CT(-a) or MR(-a)).TIA is defined as occurence of acute neurological deficit lasting less than 24 hours with confirmation of ischemia on MRI). * Patients have a kidney function eGFR\>30ml/min.

Exclusion criteria

* A history of clinical TIA, ischemic stroke or intracerebral hemorrhage * A intracerebral hemorrhage resulting from trauma, known aneurysm or underlying intracerebral malignancy. * A venous infarction, retinal infarction or amourosis fugax. * Inadequate control of the Dutch language to reliably sign an informed consent from and/or participate in the follow-up * Patients are excluded if they have a contra indication for 3T MRI.

Design outcomes

Primary

MeasureTime frameDescription
Difference of concentration biomarkers and coagulation assays between patients and controlsAt baseline and 3 month visitBiomarkers and assays of coagulation, inflammation and endothelium activation

Secondary

MeasureTime frameDescription
Recurrent venous thrombotic events10 yearsDeep venous thrombosis, pulmonary embolism, cerebral venous sinus thrombosis
Death from any cause10 years
Malignancy10 years
Bleeding complications10 yearsMinor and major bleeding complications
Vessel wall imaging on 3T MRIAt baselineDetection of vessel wall enhancement on MRI in young stroke patients
Nonfatal or fatal recurrent cardiovascular (ischemic) events10 yearsIschemic stroke or transient ischemic attack, acute coronary syndrome, peripheral artery disease

Other

MeasureTime frameDescription
Coping strategiesat 3 months visit and 6 monthsQuestionnaire about different strategies to cope with major setbacks.
Subjective cognitive outcomeat 6-month follow-upSubjective cognition will be assessed with an electronic questionnaire
Functional outcome will be assessed with Barthel Indexat 3-month visit and at annual follow-up contacts from year 1 to year 10.
Modified Rankin Scaleat 3-month visit and at annual follow-up contacts from year 1 to year 10Functional outcome will be assessed with modified Rankin Scale

Countries

Netherlands

Contacts

Primary ContactFrank-Erik De Leeuw, Prof.
frankerik.deleeuw@radboudumc.nl0031650200314
Backup ContactJanneke Spiegelenberg, MD
janneke.spiegelenberg@radboudumc.nl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026